These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37735435)

  • 1. Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes.
    Oliveira Ramos F; Rodrigues AM; Melo AT; Aguiar F; Brites L; Azevedo S; Duarte AC; Gomes JAM; Furtado C; Mourão AF; Sequeira G; Cunha I; Figueira R; Santos MJ; Fonseca JE
    Arthritis Res Ther; 2023 Sep; 25(1):177. PubMed ID: 37735435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood.
    Minden K; Horneff G; Niewerth M; Seipelt E; Aringer M; Aries P; Foeldvari I; Haas JP; Klein A; Tatsis S; Tenbrock K; Zink A; Klotsche J
    Arthritis Care Res (Hoboken); 2019 Apr; 71(4):471-481. PubMed ID: 30044538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
    Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
    Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
    Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study.
    Montag LJ; Horneff G; Hoff P; Klein A; Kallinich T; Foeldvari I; Seipelt E; Tatsis S; Peer Aries MD; Niewerth M; Klotsche J; Minden K
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36283758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
    Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
    Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life and disability in adults with juvenile idiopathic arthritis: comparison with adult-onset rheumatic diseases.
    Oliveira Ramos F; Rodrigues A; Magalhaes Martins F; Melo AT; Aguiar F; Brites L; Azevedo S; Duarte AC; Furtado C; Mourão AF; Sequeira G; Cunha I; Figueira R; Melo Gomes JA; Santos MJ; Fonseca JE
    RMD Open; 2021 Nov; 7(3):. PubMed ID: 34819385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Health Status from Early Disease to Adulthood and Associated Prognostic Factors in Juvenile Idiopathic Arthritis.
    Tollisen A; Selvaag AM; Aasland A; Lerdal A; Flatø B
    J Rheumatol; 2019 Oct; 46(10):1335-1344. PubMed ID: 30877211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Medications Are Needed for Children With Juvenile Idiopathic Arthritis.
    Brunner HI; Schanberg LE; Kimura Y; Dennos A; Co DO; Colbert RA; Fuhlbrigge RC; Goldmuntz E; Kingsbury DJ; Patty-Resk C; Mintz S; Onel K; Rider LG; Schneider R; Watts A; von Scheven E; Lovell DJ; Beukelman T;
    Arthritis Rheumatol; 2020 Nov; 72(11):1945-1951. PubMed ID: 32524767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort.
    Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T;
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt.
    Mourão AF; Santos MJ; Melo Gomes JA; Martins FM; Mendonça SC; Oliveira Ramos F; Fernandes S; Salgado M; Guedes M; Carvalho S; Costa JA; Brito I; Duarte C; Furtado C; Lopes A; Rodrigues A; Sequeira G; Branco JC; Fonseca JE; Canhão H
    Rheumatology (Oxford); 2016 Apr; 55(4):697-703. PubMed ID: 26672905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
    Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD;
    Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register.
    Anink J; Prince FH; Dijkstra M; Otten MH; Twilt M; ten Cate R; Gorter SL; Koopman-Keemink Y; van Rossum MA; Hoppenreijs EP; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2015 Nov; 54(11):1964-9. PubMed ID: 26078219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
    Baris HE; Anderson E; Sozeri B; Dedeoglu F
    Clin Rheumatol; 2018 Dec; 37(12):3263-3273. PubMed ID: 30238379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
    Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
    Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptable quality of life and low disease activity achievable among transition phase patients with rheumatic disease.
    Relas H; Kosola S
    Clin Rheumatol; 2019 Mar; 38(3):785-791. PubMed ID: 30374749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis.
    Pedersen ML; Neve-Græsbøll A; Herlin T; Glerup M
    Pediatr Rheumatol Online J; 2023 Sep; 21(1):107. PubMed ID: 37742033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study.
    Dimopoulou D; Trachana M; Pratsidou-Gertsi P; Sidiropoulos P; Kanakoudi-Tsakalidou F; Dimitroulas T; Garyfallos A
    Rheumatology (Oxford); 2017 Nov; 56(11):1928-1938. PubMed ID: 29088453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.